Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
105 hedge funds and large institutions have $339M invested in Y-mAbs Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 10 closing their positions.
11,160% more call options, than puts
Call options by funds: $563K | Put options by funds: $5K
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
15% more capital invested
Capital invested by funds: $294M → $339M (+$44.4M)
9% more funds holding
Funds holding: 96 → 105 (+9)
2.25% more ownership
Funds ownership: 55.49% → 57.75% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.1M |
| 2 |
CP
Caligan Partners
New York
|
+$7.77M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.14M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.73M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.53M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.34M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.14M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.76M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.76M |
YMAB Hedge Fund Activity: Q3 2024 in Review
105 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2024, worth a combined $339M — up 15% from $294M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new YMAB positions and 10 closed out — a net gain of 9 holders — while 38 added to existing stakes and 28 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $10.1M. The largest seller was Millennium Management, cutting an estimated $3.53M.
- 105 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2024, up from 96 in Q2 2024.
- Funds reported $339M of Y-mAbs Therapeutics stock for Q3 2024, up 15% quarter-over-quarter.
- 19 funds opened new Y-mAbs Therapeutics positions in Q3 2024 and 10 closed out, a net change of +9 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2024 was Logos Global Management, an estimated $10.1M added.
- The largest Y-mAbs Therapeutics seller in Q3 2024 was Millennium Management, an estimated $3.53M sold.
Based on aggregated 13F filings for Q3 2024.